ReviewArthritis research & therapy2003
Autoantibodies in vasculitis.
Review in Arthritis research & therapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 48 citations in OpenAlex.
- Parvovirus B19 in Rheumatic Diseases.Microorganisms · 2024Review
- Circulating Anti-Endothelial Cell Antibodies in Patients with Geographic Atrophy Related to Dry Age-Related Macular Degeneration.Medicina (Kaunas, Lithuania) · 2024Article
- B Lineage Cells in ANCA-Associated Vasculitis.International journal of molecular sciences · 2021Review
- Prevalence and pathogenicity of autoantibodies in patients with idiopathic CD4 lymphopenia.The Journal of clinical investigation · 2020Article
- Next-Generation Autoantibody Testing by Combination of Screening and Confirmation-the CytoBead® Technology.Clinical reviews in allergy & immunology · 2017Review
- Antibodies against High Mobility Group Box protein-1 (HMGB1) versus other anti-nuclear antibody fine-specificities and disease activity in systemic lupus erythematosus.Arthritis research & therapy · 2015Article
- Simultaneous automated screening and confirmatory testing for vasculitis-specific ANCA.PloS one · 2014Article
- Automated interpretation of ANCA patterns - a new approach in the serology of ANCA-associated vasculitis.Arthritis research & therapy · 2012Article
- New platform technology for comprehensive serological diagnostics of autoimmune diseases.Clinical & developmental immunology · 2012Review
- Autoantigenic nuclear proteins of a clinically atypical renal vasculitis.Journal of autoimmune diseases · 2008Article
- Neutrophil surface presentation of the anti-neutrophil cytoplasmic antibody-antigen proteinase 3 depends on N-terminal processing.Clinical and experimental immunology · 2008Article
- Microscopic polyangiitis with sexual and reproductive system involvement: first description of a case.Internal and emergency medicine · 2008Article
- The potential utility of B cell-directed biologic therapy in autoimmune diseases.Rheumatology international · 2008Review
- Bench-to-bedside review: pulmonary-renal syndromes--an update for the intensivist.Critical care (London, England) · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Before the mid-1980s the only autoantibody widely used to assist in diagnosing vasculitic disease was IgG antibody to the alpha(3) domain of the noncollagenous part of type IV collagen (anti-glomerular basement membrane). Since that time, antineutrophil cytoplasmic antibodies (ANCAs) directed at the azurophilic granule proteins proteinase-3 and myeloperoxidase have been established as clinically useful autoantibodies to support a diagnosis of Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and limited forms of these primary, small vessel necrotizing and often granulomatous vasculitides. The establishment of standardized methods for identifying those antibodies was needed before they could be used in clinical practice. The levels of both types of ANCAs tend to increase in parallel with the degree of clinical disease activity, and they decrease with successful immunosuppressive therapy. More than one assay may have to be used to discover imminent exacerbations in proteinase-3-ANCA associated syndromes. Although autoantibodies to endothelial cells may be important players in the pathogenesis of several vasculitic conditions, they have not gained clinical popularity because of lack of standardized detection methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.